Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523422 | 0.87 | POLB (0.42) | POLBPDE4BTP53MAPTTHRB | |
| SCHEMBL3434006 | 0.85 | POLB (0.38) | POLBPDE4BTP53MAPTTHRB | |
| SCHEMBL3434005 | 0.85 | POLB (0.38) | POLBPDE4BTP53MAPTTHRB | |
| SCHEMBL6519249 | 0.80 | PDE4B (0.42) | POLBPDE4BTP53MAPTTHRB | |
| SCHEMBL6524011 | 0.77 | MAPT (0.48) | PDE4BTP53MAPTTHRBLMNA | |
| SCHEMBL31386180 | 0.73 | PDE4B (0.52) | PDE4BMAPTTRPV3SCN9AJAK2 | |
| SCHEMBL22810473 | 0.71 | PDE4B (0.52) | POLBPDE4BMAPTTRPV3JAK2 | |
| SCHEMBL31386029 | 0.70 | PDE4B (0.53) | PDE4BSCN9AJAK2JAK1 | |
| SCHEMBL31385927 | 0.70 | PDE4B (0.50) | PDE4BMAPTTRPV3SCN9AJAK2 | |
| SCHEMBL31385735 | 0.69 | PDE4B (0.54) | PDE4BTP53MAPTTHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362030-B2 | Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-01-29 | — | — | US | disclosed |
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053911-A1 | TRICYCLIC DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | PARP1, PARP2, PARP11 | POLB 29/4885PDE4B 4172/4885TP53 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.